As immune checkpoint therapy, especially targeting BTLA, is becoming widely available to cancer patients, it is critical to understand the underlying function and mechanism of these immune checkpoints, thus benefiting patients with advanced cancer. The gene discussed is BTLA; the disease is cancer.